lvrachЛечащий ВрачLechaschi Vrach1560-51752687-1181lvrach-575Research ArticleСтатьиПрименение мультипотентных мезенхимальных стромальных клеток костного мозга при трансплантации почкиUse of marrow multipotent mesenchymal (stromal) cells in renal transplantationХубутияМ. Ш.KhubutiaM. Sh.noemail@neicon.ruБоровковаН. В.BorovkovaN. V.noemail@neicon.ruРжевскаяО. Н.RzhevskayaO. N.noemail@neicon.ruПинчукА. В.PinchukA. V.noemail@neicon.ruВасильченковД. А.VasilchenkovD. A.wrestler931@yandex.ruГБУЗ НИИ СП им. Н. В. Склифософского ДЗМRussian FederationФГБОУ ВО МГМСУ им. А. И. Евдокимова МЗ РФRussian Federation201823062021091616Copyright © Хубутия М.Ш., Боровкова Н.В., Ржевская О.Н., Пинчук А.В., Васильченков Д.А., 20212021Хубутия М.Ш., Боровкова Н.В., Ржевская О.Н., Пинчук А.В., Васильченков Д.А.Khubutia M.S., Borovkova N.V., Rzhevskaya O.N., Pinchuk A.V., Vasilchenkov D.A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://journal.lvrach.ru/jour/article/view/575

Несмотря на достижения иммуносупрессивной терапии пациентов с пересаженными органами, сроки функционирования трансплантатов не удается увеличить на протяжении нескольких десятилетий. В качестве средства, способного изменить данную ситуацию, рассматриваются мультипотентные мезенхимальные (стромальные) клетки костного мозга (ММСК КМ). В данной публикации представлен анализ экспериментального и клинического опыта использования ММСК при трансплантации почки.

Despite the achievements of immunosuppressive therapy in patients after renal transplantation, duration of graft survival remains unchanged during last few decades. Marrow multipotent mesenchymal (stromal) stem cells (BM MMSC) is a potential tool to influence this situation. Actual experience and gaps in BM MSC data have been analyzed in current publication. 

СимпозиумУронефрологияМультипотентные мезенхимальные стромальные клетки костного мозгаПересадка почкиТолерантностьИммуносупрессияmarrow multipotent mesenchymal stem cellsrenal transplantationtoleranceimmunosuppressionReferencesLiyanage T. et al. Worldwide access to treatment for end-stage kidney disease: a systematic review // The Lancet. 2015. Т. 385. № 9981. С. 1975–1982.Liyanage T. et al. Worldwide access to treatment for end-stage kidney disease: a systematic review // The Lancet. 2015. Т. 385. № 9981. С. 1975–1982.Webster A. C. et al. Chronic kidney disease // The Lancet. 2017. Т. 389. № 10075. С. 1238–1252.Webster A. C. et al. Chronic kidney disease // The Lancet. 2017. Т. 389. № 10075. С. 1238–1252.Готье С. В. Иммуносупрессия при трансплантации солидных органов. Тверь: Триада. 2011. Т. 472.Готье С. В. Иммуносупрессия при трансплантации солидных органов. Тверь: Триада. 2011. Т. 472.Bamoulid J. et al. The need for minimization strategies: current problems of immunosuppression // Transplant International. 2015. Т. 28. № 8. С. 891–900.Bamoulid J. et al. The need for minimization strategies: current problems of immunosuppression // Transplant International. 2015. Т. 28. № 8. С. 891–900.Casiraghi F., Perico N., Remuzzi G. Mesenchymal stromal cells for tolerance induction in organ transplantation // Human immunology. 2017.Casiraghi F., Perico N., Remuzzi G. Mesenchymal stromal cells for tolerance induction in organ transplantation // Human immunology. 2017.Friedenstein A. J., Chailakhjan R. K., Lalykina K. S. The development of fibroblast colonies in monolayer cultures of guinea-pig bone marrow and spleen cells // Cell Proliferation. 1970. Т. 3. № 4. С. 393–403.Friedenstein A. J., Chailakhjan R. K., Lalykina K. S. The development of fibroblast colonies in monolayer cultures of guinea-pig bone marrow and spleen cells // Cell Proliferation. 1970. Т. 3. № 4. С. 393–403.Orkin S. H., Zon L. I. Hematopoiesis: an evolving paradigm for stem cell biology // Cell. 2008. Т. 132. № 4. С. 631–644.Orkin S. H., Zon L. I. Hematopoiesis: an evolving paradigm for stem cell biology // Cell. 2008. Т. 132. № 4. С. 631–644.Appelbaum F. R. Hematopoietic-cell transplantation at 50 // New England Journal of Medicine. 2007. Т. 357. № 15. С. 1472–1475.Appelbaum F. R. Hematopoietic-cell transplantation at 50 // New England Journal of Medicine. 2007. Т. 357. № 15. С. 1472–1475.Dominici M. et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement // Cytotherapy. 2006. Т. 8. № 4. С. 315–317.Dominici M. et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement // Cytotherapy. 2006. Т. 8. № 4. С. 315–317.Friedenstein A. J., Piatetzky-Shapiro I. I., Petrakova K. V. Osteogenesis in transplants of bone marrow cells // Development. 1966. Т. 16. № 3. С. 381–390.Friedenstein A. J., Piatetzky-Shapiro I. I., Petrakova K. V. Osteogenesis in transplants of bone marrow cells // Development. 1966. Т. 16. № 3. С. 381–390.Le Blanc K. et al. Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells // The Lancet. 2004. Т. 363. № 9419. С. 1439–1441.Le Blanc K. et al. Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells // The Lancet. 2004. Т. 363. № 9419. С. 1439–1441.Casiraghi F., Perico N., Remuzzi G. Mesenchymal stromal cells to promote solid organ transplantation tolerance // Current opinion in organ transplantation. 2013, 18 (1), 51–58. DOI: 10.1097/MOT.0 b013 e32835 c5016.Casiraghi F., Perico N., Remuzzi G. Mesenchymal stromal cells to promote solid organ transplantation tolerance // Current opinion in organ transplantation. 2013, 18 (1), 51–58. DOI: 10.1097/MOT.0 b013 e32835 c5016.Casiraghi F., Perico N., Remuzzi G. Mesenchymal stromal cells to promote solid organ transplantation tolerance // Current opinion in organ transplantation. 2013. Т. 18. № 1. С. 51–58.Casiraghi F., Perico N., Remuzzi G. Mesenchymal stromal cells to promote solid organ transplantation tolerance // Current opinion in organ transplantation. 2013. Т. 18. № 1. С. 51–58.Zhou H. P. et al. Administration of donor-derived mesenchymal stem cells can prolong the survival of rat cardiac allograft // Transplantation proceedings. Elsevier, 2006. Т. 38. № 9. С. 3046–3051.Zhou H. P. et al. Administration of donor-derived mesenchymal stem cells can prolong the survival of rat cardiac allograft // Transplantation proceedings. Elsevier, 2006. Т. 38. № 9. С. 3046–3051.Casiraghi F. et al. Pretransplant infusion of mesenchymal stem cells prolongs the survival of a semiallogeneic heart transplant through the generation of regulatory T cells // The Journal of Immunology. 2008. Т. 181. № 6. С. 3933–3946.Casiraghi F. et al. Pretransplant infusion of mesenchymal stem cells prolongs the survival of a semiallogeneic heart transplant through the generation of regulatory T cells // The Journal of Immunology. 2008. Т. 181. № 6. С. 3933–3946.Ryan J. M. et al. Mesenchymal stem cells avoid allogeneic rejection // Journal of Inflammation. 2005. Т. 2. № 1. С. 8.Ryan J. M. et al. Mesenchymal stem cells avoid allogeneic rejection // Journal of Inflammation. 2005. Т. 2. № 1. С. 8.Tu Z. et al. Mesenchymal stem cells inhibit complement activation by secreting factor H // Stem cells and development. 2010. Т. 19. № 11. С. 1803–1809.Tu Z. et al. Mesenchymal stem cells inhibit complement activation by secreting factor H // Stem cells and development. 2010. Т. 19. № 11. С. 1803–1809.Moll G. et al. Mesenchymal stromal cells engage complement and complement receptor bearing innate effector cells to modulate immune responses // PloS one. 2011. Т. 6. № 7. С. e21703.Moll G. et al. Mesenchymal stromal cells engage complement and complement receptor bearing innate effector cells to modulate immune responses // PloS one. 2011. Т. 6. № 7. С. e21703.Brandau S. et al. Tissue-resident mesenchymal stem cells attract peripheral blood neutrophils and enhance their inflammatory activity in response to microbial challenge // Journal of leukocyte Biology. 2010. Т. 88. № 5. С. 1005–1015.Brandau S. et al. Tissue-resident mesenchymal stem cells attract peripheral blood neutrophils and enhance their inflammatory activity in response to microbial challenge // Journal of leukocyte Biology. 2010. Т. 88. № 5. С. 1005–1015.Jiang X. X. et al. Human mesenchymal stem cells inhibit differentiation and function of monocyte-derived dendritic cells // Blood. 2005. Т. 105. № 10. С. 4120–4126.Jiang X. X. et al. Human mesenchymal stem cells inhibit differentiation and function of monocyte-derived dendritic cells // Blood. 2005. Т. 105. № 10. С. 4120–4126.Nauta A. J. et al. Mesenchymal stem cells inhibit generation and function of both CD34+-derived and monocyte-derived dendritic cells // The Journal of Immunology. 2006. Т. 177. № 4. С. 2080–2087.Nauta A. J. et al. Mesenchymal stem cells inhibit generation and function of both CD34+-derived and monocyte-derived dendritic cells // The Journal of Immunology. 2006. Т. 177. № 4. С. 2080–2087.Spaggiari G. M. et al. Mesenchymal stem cell-natural killer cell interactions: evidence that activated NK cells are capable of killing MSCs, whereas MSCs can inhibit IL-2-induced NK-cell proliferation // Blood. 2006. Т. 107. № 4. С. 1484–1490.Spaggiari G. M. et al. Mesenchymal stem cell-natural killer cell interactions: evidence that activated NK cells are capable of killing MSCs, whereas MSCs can inhibit IL-2-induced NK-cell proliferation // Blood. 2006. Т. 107. № 4. С. 1484–1490.Spaggiari G. M. et al. Mesenchymal stem cells inhibit natural killer–cell proliferation, cytotoxicity, and cytokine production: role of indoleamine 2, 3-dioxygenase and prostaglandin E2 // Blood. 2008. Т. 111. № 3. С. 1327–1333.Spaggiari G. M. et al. Mesenchymal stem cells inhibit natural killer–cell proliferation, cytotoxicity, and cytokine production: role of indoleamine 2, 3-dioxygenase and prostaglandin E2 // Blood. 2008. Т. 111. № 3. С. 1327–1333.Chiesa S. et al. Mesenchymal stem cells impair in vivo T-cell priming by dendritic cells // Proceedings of the National Academy of Sciences. 2011. Т. 108. № 42. С. 17384–17389.Chiesa S. et al. Mesenchymal stem cells impair in vivo T-cell priming by dendritic cells // Proceedings of the National Academy of Sciences. 2011. Т. 108. № 42. С. 17384–17389.Du Rocher B. et al. Mesenchymal stromal cells impair the differentiation of CD14++ CD16 — CD64+ classical monocytes into CD14++ CD16+ CD64++ activate monocytes // Cytotherapy. 2012. Т. 14. № 1. С. 12–25.Du Rocher B. et al. Mesenchymal stromal cells impair the differentiation of CD14++ CD16 — CD64+ classical monocytes into CD14++ CD16+ CD64++ activate monocytes // Cytotherapy. 2012. Т. 14. № 1. С. 12–25.Kim J., Hematti P. Mesenchymal stem cell-educated macrophages: A novel type of alternatively activated macrophages // Experimental hematology. 2009. Т. 37. № 12. С. 1445–1453.Kim J., Hematti P. Mesenchymal stem cell-educated macrophages: A novel type of alternatively activated macrophages // Experimental hematology. 2009. Т. 37. № 12. С. 1445–1453.Di Nicola M. et al. Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli // Blood. 2002. Т. 99. № 10. С. 3838–3843.Di Nicola M. et al. Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli // Blood. 2002. Т. 99. № 10. С. 3838–3843.William T. T. et al. Suppression of allogeneic T-cell proliferation by human marrow stromal cells: implications in transplantation // Transplantation. 2003. Т. 75. № 3. С. 389–397.William T. T. et al. Suppression of allogeneic T-cell proliferation by human marrow stromal cells: implications in transplantation // Transplantation. 2003. Т. 75. № 3. С. 389–397.Le Blanc K. et al. Mesenchymal stem cells inhibit and stimulate mixed lymphocyte cultures and mitogenic responses independently of the major histocompatibility complex // Scandinavian journal of immunology. 2003. Т. 57. № 1. С. 11–20.Le Blanc K. et al. Mesenchymal stem cells inhibit and stimulate mixed lymphocyte cultures and mitogenic responses independently of the major histocompatibility complex // Scandinavian journal of immunology. 2003. Т. 57. № 1. С. 11–20.Glennie S. et al. Bone marrow mesenchymal stem cells induce division arrest anergy of activated T cells // Blood. 2005. Т. 105. № 7. С. 2821–2827.Glennie S. et al. Bone marrow mesenchymal stem cells induce division arrest anergy of activated T cells // Blood. 2005. Т. 105. № 7. С. 2821–2827.Duffy M. M. et al. Mesenchymal stem cell effects on T-cell effector pathways // Stem cell research & therapy. 2011. Т. 2. № 4. С. 34.Duffy M. M. et al. Mesenchymal stem cell effects on T-cell effector pathways // Stem cell research & therapy. 2011. Т. 2. № 4. С. 34.Ghannam S. et al. Mesenchymal stem cells inhibit human Th17 cell differentiation and function and induce a T regulatory cell phenotype // The Journal of Immunology. 2010. Т. 185. № 1. С. 302–312.Ghannam S. et al. Mesenchymal stem cells inhibit human Th17 cell differentiation and function and induce a T regulatory cell phenotype // The Journal of Immunology. 2010. Т. 185. № 1. С. 302–312.English K. et al. Cell contact, prostaglandin E2 and transforming growth factor beta 1 play non-redundant roles in human mesenchymal stem cell induction of CD4+ CD25 Highforkhead box P3+ regulatory T cells // Clinical & Experimental Immunology. 2009. Т. 156. № 1. С. 149–160.English K. et al. Cell contact, prostaglandin E2 and transforming growth factor beta 1 play non-redundant roles in human mesenchymal stem cell induction of CD4+ CD25 Highforkhead box P3+ regulatory T cells // Clinical & Experimental Immunology. 2009. Т. 156. № 1. С. 149–160.Tabera S. et al. The effect of mesenchymal stem cells on the viability, proliferation and differentiation of B-lymphocytes // Haematologica. 2008. Т. 93. № 9. С. 1301–1309.Tabera S. et al. The effect of mesenchymal stem cells on the viability, proliferation and differentiation of B-lymphocytes // Haematologica. 2008. Т. 93. № 9. С. 1301–1309.Peng Y. et al. Mesenchymal stromal cells infusions improve refractory chronic graft versus host disease through an increase of CD5+ regulatory B cells producing interleukin 10 // Leukemia. 2015. Т. 29. № 3. С. 636.Peng Y. et al. Mesenchymal stromal cells infusions improve refractory chronic graft versus host disease through an increase of CD5+ regulatory B cells producing interleukin 10 // Leukemia. 2015. Т. 29. № 3. С. 636.Franquesa M. et al. Human adipose tissue-derived mesenchymal stem cells abrogate plasmablast formation and induce regulatory B cells independently of T helper cells // Stem cells. 2015. Т. 33. № 3. С. 880–891.Franquesa M. et al. Human adipose tissue-derived mesenchymal stem cells abrogate plasmablast formation and induce regulatory B cells independently of T helper cells // Stem cells. 2015. Т. 33. № 3. С. 880–891.Prockop D. J. Repair of tissues by adult stem/progenitor cells (MSCs): controversies, myths, and changing paradigms // Molecular Therapy. 2009. Т. 17. № 6. С. 939–946.Prockop D. J. Repair of tissues by adult stem/progenitor cells (MSCs): controversies, myths, and changing paradigms // Molecular Therapy. 2009. Т. 17. № 6. С. 939–946.Da Silva Meirelles L., Caplan A. I., Nardi N. B. In search of the in vivo identity of mesenchymal stem cells // Stem cells. 2008. Т. 26. № 9. С. 2287–2299.Da Silva Meirelles L., Caplan A. I., Nardi N. B. In search of the in vivo identity of mesenchymal stem cells // Stem cells. 2008. Т. 26. № 9. С. 2287–2299.Block G. J. et al. Multipotent stromal cells are activated to reduce apoptosis in part by upregulation and secretion of stanniocalcin-1 // Stem cells. 2009. Т. 27. № 3. С. 670–681.Block G. J. et al. Multipotent stromal cells are activated to reduce apoptosis in part by upregulation and secretion of stanniocalcin-1 // Stem cells. 2009. Т. 27. № 3. С. 670–681.Lee R. H. et al. Intravenous hMSCs improve myocardial infarction in mice because cells embolized in lung are activated to secrete the anti-inflammatory protein TSG-6 // Cell stem cell. 2009. Т. 5. № 1. С. 54–63.Lee R. H. et al. Intravenous hMSCs improve myocardial infarction in mice because cells embolized in lung are activated to secrete the anti-inflammatory protein TSG-6 // Cell stem cell. 2009. Т. 5. № 1. С. 54–63.Jia X. et al. Bone marrow mesenchymal stromal cells ameliorate angiogenesis and renal damage via promoting PI3 k-Akt signaling pathway activation in vivo // Cytotherapy. 2016. Т. 18. № 7. С. 838–845.Jia X. et al. Bone marrow mesenchymal stromal cells ameliorate angiogenesis and renal damage via promoting PI3 k-Akt signaling pathway activation in vivo // Cytotherapy. 2016. Т. 18. № 7. С. 838–845.Hou, Yu, et al. IL-8 enhances the angiogenic potential of human bone marrow mesenchymal stem cells by increasing vascular endothelial growth factor // Cell biology international. 2014: 38, 1050–1059.Hou, Yu, et al. IL-8 enhances the angiogenic potential of human bone marrow mesenchymal stem cells by increasing vascular endothelial growth factor // Cell biology international. 2014: 38, 1050–1059.Bartholomew A. et al. Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo // Experimental hematology. 2002. Т. 30. № 1. С. 42–48.Bartholomew A. et al. Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo // Experimental hematology. 2002. Т. 30. № 1. С. 42–48.Zhou H. P. et al. Administration of donor-derived mesenchymal stem cells can prolong the survival of rat cardiac allograft // Transplantation proceedings. Elsevier, 2006. Т. 38. № 9. С. 3046–3051.Zhou H. P. et al. Administration of donor-derived mesenchymal stem cells can prolong the survival of rat cardiac allograft // Transplantation proceedings. Elsevier, 2006. Т. 38. № 9. С. 3046–3051.Casiraghi F. et al. Pretransplant infusion of mesenchymal stem cells prolongs the survival of a semiallogeneic heart transplant through the generation of regulatory T cells // The Journal of Immunology. 2008. Т. 181. № 6. С. 3933–3946.Casiraghi F. et al. Pretransplant infusion of mesenchymal stem cells prolongs the survival of a semiallogeneic heart transplant through the generation of regulatory T cells // The Journal of Immunology. 2008. Т. 181. № 6. С. 3933–3946.Zhang W., Qin C., Zhou Z. M. Mesenchymal stem cells modulate immune responses combined with cyclosporine in a rat renal transplantation model // Transplantation proceedings. Elsevier, 2007. Т. 39. № 10. С. 3404–3408.Zhang W., Qin C., Zhou Z. M. Mesenchymal stem cells modulate immune responses combined with cyclosporine in a rat renal transplantation model // Transplantation proceedings. Elsevier, 2007. Т. 39. № 10. С. 3404–3408.De Martino M. et al. Mesenchymal stem cells infusion prevents acute cellular rejection in rat kidney transplantation // Transplantation proceedings. Elsevier, 2010. Т. 42. № 4. С. 1331–1335.De Martino M. et al. Mesenchymal stem cells infusion prevents acute cellular rejection in rat kidney transplantation // Transplantation proceedings. Elsevier, 2010. Т. 42. № 4. С. 1331–1335.Casiraghi F. et al. Localization of mesenchymal stromal cells dictates their immune or proinflammatory effects in kidney transplantation // American Journal of Transplantation. 2012. Т. 12. № 9. С. 2373–2383.Casiraghi F. et al. Localization of mesenchymal stromal cells dictates their immune or proinflammatory effects in kidney transplantation // American Journal of Transplantation. 2012. Т. 12. № 9. С. 2373–2383.Ge W. et al. Regulatory T-cell generation and kidney allograft tolerance induced by mesenchymal stem cells associated with indoleamine 2, 3-dioxygenase expression // Transplantation. 2010. Т. 90. № 12. С. 1312–1320.Ge W. et al. Regulatory T-cell generation and kidney allograft tolerance induced by mesenchymal stem cells associated with indoleamine 2, 3-dioxygenase expression // Transplantation. 2010. Т. 90. № 12. С. 1312–1320.Онищенко Н. А. и др. Влияние мезенхимальных стволовых клеток костного мозга на развитие посттрансплантационных изменений в почке // Вестник трансплантологии и искусственных органов. 2016. Т. 18. № 1. С. 45–52.Онищенко Н. А. и др. Влияние мезенхимальных стволовых клеток костного мозга на развитие посттрансплантационных изменений в почке // Вестник трансплантологии и искусственных органов. 2016. Т. 18. № 1. С. 45–52.Seok J. et al. Genomic responses in mouse models poorly mimic human inflammatory diseases // Proceedings of the National Academy of Sciences. 2013. Т. 110. № 9. С. 3507–3512.Seok J. et al. Genomic responses in mouse models poorly mimic human inflammatory diseases // Proceedings of the National Academy of Sciences. 2013. Т. 110. № 9. С. 3507–3512.Mao F. et al. Mesenchymal stem cells and their therapeutic applications in inflammatory bowel disease // Oncotarget. 2017. Т. 8. № 23. С. 38008.Mao F. et al. Mesenchymal stem cells and their therapeutic applications in inflammatory bowel disease // Oncotarget. 2017. Т. 8. № 23. С. 38008.Князев О. В. и др. Комбинированная клеточная антицитокиновая терапия способствует более выраженному уменьшению степеней воспаления слизистой оболочки кишки при болезни Крона // Доказательная гастроэнтерология. 2016. Т. 7. № 1. С. 66 a-67.Князев О. В. и др. Комбинированная клеточная антицитокиновая терапия способствует более выраженному уменьшению степеней воспаления слизистой оболочки кишки при болезни Крона // Доказательная гастроэнтерология. 2016. Т. 7. № 1. С. 66 a-67.Lu D. et al. Comparison of bone marrow mesenchymal stem cells with bone marrow-derived mononuclear cells for treatment of diabetic critical limb ischemia and foot ulcer: a double-blind, randomized, controlled trial // Diabetes research and clinical practice. 2011. Т. 92. № 1. С. 26–36.Lu D. et al. Comparison of bone marrow mesenchymal stem cells with bone marrow-derived mononuclear cells for treatment of diabetic critical limb ischemia and foot ulcer: a double-blind, randomized, controlled trial // Diabetes research and clinical practice. 2011. Т. 92. № 1. С. 26–36.Prasad V. K. et al. Efficacy and safety of ex vivo cultured adult human mesenchymal stem cells (Prochymal™) in pediatric patients with severe refractory acute graft-versus-host disease in a compassionate use study // Biology of Blood and Marrow Transplantation. 2011. Т. 17. № 4. С. 534–541.Prasad V. K. et al. Efficacy and safety of ex vivo cultured adult human mesenchymal stem cells (Prochymal™) in pediatric patients with severe refractory acute graft-versus-host disease in a compassionate use study // Biology of Blood and Marrow Transplantation. 2011. Т. 17. № 4. С. 534–541.Griffin M. D. et al. Concise review: adult mesenchymal stromal cell therapy for inflammatory diseases: how well are we joining the dots? // Stem Cells. 2013. Т. 31. № 10. С. 2033–2041.Griffin M. D. et al. Concise review: adult mesenchymal stromal cell therapy for inflammatory diseases: how well are we joining the dots? // Stem Cells. 2013. Т. 31. № 10. С. 2033–2041.Verstockt B. et al. New treatment options for inflammatory bowel diseases // Journal of gastroenterology. 2018. С. 1–6.Verstockt B. et al. New treatment options for inflammatory bowel diseases // Journal of gastroenterology. 2018. С. 1–6.Perico N. et al. Autologous mesenchymal stromal cells and kidney transplantation: a pilot study of safety and clinical feasibility // Clinical Journal of the American Society of Nephrology. 2011. Т. 6. № 2. С. 412–422.Perico N. et al. Autologous mesenchymal stromal cells and kidney transplantation: a pilot study of safety and clinical feasibility // Clinical Journal of the American Society of Nephrology. 2011. Т. 6. № 2. С. 412–422.Reinders M. E. J. et al. Autologous bone marrow-derived mesenchymal stromal cells for the treatment of allograft rejection after renal transplantation: Results of a phase I study // Stem cells translational medicine. 2013. Т. 2. № 2. С. 107–111.Reinders M. E. J. et al. Autologous bone marrow-derived mesenchymal stromal cells for the treatment of allograft rejection after renal transplantation: Results of a phase I study // Stem cells translational medicine. 2013. Т. 2. № 2. С. 107–111.Reinders M. E. J. et al. Autologous bone marrow derived mesenchymal stromal cell therapy in combination with everolimus to preserve renal structure and function in renal transplant recipients // Journal of translational medicine. 2014. Т. 12. № 1. С. 331.Reinders M. E. J. et al. Autologous bone marrow derived mesenchymal stromal cell therapy in combination with everolimus to preserve renal structure and function in renal transplant recipients // Journal of translational medicine. 2014. Т. 12. № 1. С. 331.Casiraghi F. et al. Localization of mesenchymal stromal cells dictates their immune or proinflammatory effects in kidney transplantation // American Journal of Transplantation. 2012. Т. 12. № 9. С. 2373–2383.Casiraghi F. et al. Localization of mesenchymal stromal cells dictates their immune or proinflammatory effects in kidney transplantation // American Journal of Transplantation. 2012. Т. 12. № 9. С. 2373–2383.Perico N. et al. Mesenchymal stromal cells and kidney transplantation: pretransplant infusion protects from graft dysfunction while fostering immunoregulation // Transplant International. 2013. Т. 26. № 9. С. 867–878.Perico N. et al. Mesenchymal stromal cells and kidney transplantation: pretransplant infusion protects from graft dysfunction while fostering immunoregulation // Transplant International. 2013. Т. 26. № 9. С. 867–878.Tan J. et al. Induction therapy with autologous mesenchymal stem cells in living-related kidney transplants: a randomized controlled trial // Jama. 2012. Т. 307. № 11. С. 1169–1177.Tan J. et al. Induction therapy with autologous mesenchymal stem cells in living-related kidney transplants: a randomized controlled trial // Jama. 2012. Т. 307. № 11. С. 1169–1177.Mudrabettu C. et al. Safety and efficacy of autologous mesenchymal stromal cells transplantation in patients undergoing living donor kidney transplantation: a pilot study // Nephrology. 2015. Т. 20. № 1. С. 25–33.Mudrabettu C. et al. Safety and efficacy of autologous mesenchymal stromal cells transplantation in patients undergoing living donor kidney transplantation: a pilot study // Nephrology. 2015. Т. 20. № 1. С. 25–33.Le Blanc K. et al. Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study // The Lancet. 2008. Т. 371. № 9624. С. 1579–1586.Le Blanc K. et al. Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study // The Lancet. 2008. Т. 371. № 9624. С. 1579–1586.Ball L. M. et al. Multiple infusions of mesenchymal stromal cells induce sustained remission in children with steroid-refractory, grade III–IV acute graft-versus-host disease // British journal of haematology. 2013. Т. 163. № 4. С. 501–509.Ball L. M. et al. Multiple infusions of mesenchymal stromal cells induce sustained remission in children with steroid-refractory, grade III–IV acute graft-versus-host disease // British journal of haematology. 2013. Т. 163. № 4. С. 501–509.Reinders M. E. J. et al. Mesenchymal stromal cell therapy for solid organ transplantation // Transplantation. 2018. Т. 102. № 1. С. 35–43.Reinders M. E. J. et al. Mesenchymal stromal cell therapy for solid organ transplantation // Transplantation. 2018. Т. 102. № 1. С. 35–43.Buron F. et al. Human mesenchymal stem cells and immunosuppressive drug interactions in allogeneic responses: an in vitro study using human cells // Transplantation proceedings. Elsevier, 2009. Т. 41. № 8. С. 3347–3352.Buron F. et al. Human mesenchymal stem cells and immunosuppressive drug interactions in allogeneic responses: an in vitro study using human cells // Transplantation proceedings. Elsevier, 2009. Т. 41. № 8. С. 3347–3352.Hoogduijn M. J. et al. Susceptibility of human mesenchymal stem cells to tacrolimus, mycophenolic acid, and rapamycin // Transplantation. 2008. Т. 86. № 9. С. 1283–1291.Hoogduijn M. J. et al. Susceptibility of human mesenchymal stem cells to tacrolimus, mycophenolic acid, and rapamycin // Transplantation. 2008. Т. 86. № 9. С. 1283–1291.Hajkova M. et al. Mesenchymal Stem Cells Attenuate the Adverse Effects of Immunosuppressive Drugs on Distinct T Cell Subopulations // Stem Cell Reviews and Reports. 2017. Т. 13. № 1. С. 104–115.Hajkova M. et al. Mesenchymal Stem Cells Attenuate the Adverse Effects of Immunosuppressive Drugs on Distinct T Cell Subopulations // Stem Cell Reviews and Reports. 2017. Т. 13. № 1. С. 104–115.Popp F. C. et al. Mesenchymal stem cells can induce long-term acceptance of solid organ allografts in synergy with low-dose mycophenolate // Transplant immunology. 2008. Т. 20. № 1–2. С. 55–60.Popp F. C. et al. Mesenchymal stem cells can induce long-term acceptance of solid organ allografts in synergy with low-dose mycophenolate // Transplant immunology. 2008. Т. 20. № 1–2. С. 55–60.Eggenhofer E. et al. Features of synergism between mesenchymal stem cells and immunosuppressive drugs in a murine heart transplantation model // Transplant immunology. 2011. Т. 25. № 2–3. С. 141–147.Eggenhofer E. et al. Features of synergism between mesenchymal stem cells and immunosuppressive drugs in a murine heart transplantation model // Transplant immunology. 2011. Т. 25. № 2–3. С. 141–147.Fulginiti V. A. et al. Infections in recipients of liver homografts // Transplantation. 1969. Т. 7. № 3. С. 205.Fulginiti V. A. et al. Infections in recipients of liver homografts // Transplantation. 1969. Т. 7. № 3. С. 205.Vajdic C. M., van Leeuwen M. T. Cancer incidence and risk factors after solid organ transplantation // International journal of cancer. 2009. Т. 125. № 8. С. 1747–1754.Vajdic C. M., van Leeuwen M. T. Cancer incidence and risk factors after solid organ transplantation // International journal of cancer. 2009. Т. 125. № 8. С. 1747–1754.Casiraghi F. et al. Multipotent mesenchymal stromal cell therapy and risk of malignancies // Stem Cell Reviews and Reports. 2013. Т. 9. № 1. С. 65–79.Casiraghi F. et al. Multipotent mesenchymal stromal cell therapy and risk of malignancies // Stem Cell Reviews and Reports. 2013. Т. 9. № 1. С. 65–79.Хубутия М. Ш. и др. Первый опыт успешной трансплантации тонкой кишки в в институте скорой помощи им. Н. В. Склифосовского // Журнал им. НВ Склифосовского «Неотложная медицинская помощь». 2016. № 3. С. 12–22.Хубутия М. Ш. и др. Первый опыт успешной трансплантации тонкой кишки в в институте скорой помощи им. Н. В. Склифосовского // Журнал им. НВ Склифосовского «Неотложная медицинская помощь». 2016. № 3. С. 12–22.Von Bahr L. et al. Analysis of tissues following mesenchymal stromal cell therapy in humans indicates limited long-term engraftment and no ectopic tissue formation // Stem cells. 2012. Т. 30. № 7. С. 1575–1578.Von Bahr L. et al. Analysis of tissues following mesenchymal stromal cell therapy in humans indicates limited long-term engraftment and no ectopic tissue formation // Stem cells. 2012. Т. 30. № 7. С. 1575–1578.Moermans C. et al. Impact of cotransplantation of mesenchymal stem cells on lung function after unrelated allogeneic hematopoietic stem cell transplantation following non-myeloablative conditioning // Transplantation. 2014. Т. 98. № 3. С. 348–353.Moermans C. et al. Impact of cotransplantation of mesenchymal stem cells on lung function after unrelated allogeneic hematopoietic stem cell transplantation following non-myeloablative conditioning // Transplantation. 2014. Т. 98. № 3. С. 348–353.

The authors declare that there are no conflicts of interest present.